Base-case cost-effectiveness results (discounted)
| Usual care (PRP at HR-PDR) | Intervention (early PRP at severe NPDR) | |
| Deterministic | ||
| Total mean costs (£) | £3853 | £2753 |
| Total mean QALYs | 7.8236 | 7.9572 |
| Incremental costs (£)/QALYs | −£1101/0.1337 | |
| ICER (cost per QALY gained) | Dominated | |
| Probabilistic | ||
| Total mean costs (£) | £3858 | £2746 |
| Total mean QALYs | 7.8332 | 7.9624 |
| Incremental costs (£)/QALYs | −£1112/0.1292 | |
| ICER (cost per QALY gained) | Dominated | |
table 4.
HR-PDR, high-risk proliferative diabetic retinopathy; ICER, incremental cost-effectiveness ratio; NPDR, non-proliferative diabetic retinopathy; PRP, panretinal photocoagulation; QALYs, quality-adjusted life years.